A kind of cephalaenopsis preparation and preparation method thereof
By forming an inclusion compound with β-cyclodextrin and combining other auxiliary materials, Qianjin Tengsu Oral Lozeng is prepared, which solves the problem of low oral bioavailability of Qianjin Tengsu, and achieves a significant effect of improving bioavailability and improving taste.
Patent Information
- Application Number
- CN202410118718.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-01-29
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-01-29
AI Technical Summary
The oral administration of Qianjin Tengsu is not easy to absorb and has a low bioavailability, which affects its efficacy. It is difficult for the prior art to provide a new dosage form with higher bioavailability.
By forming an inclusion compound with β-cyclodextrin and combining aspartame, dextrin, sodium carboxymethyl starch and talc, Qianjin Tengsu oral lozeng is prepared, and the oral administration method is adopted to improve bioavailability .
It significantly improves the bioavailability of Qianjin Tengsu, improves the taste and taste of the oral lozenges, and the absolute bioavailability reaches 27.6%. The preparation process is simple, has no side effects, and is easy to promote.
Smart Images

Figure CN118141948B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of preparation of stephania cephalaenopsis preparations, and in particular relates to a stephania cephalaenopsis preparation and a preparation method thereof. Background Art
[0002] Stephania cerebroside, also known as Stephania capitis, is a dibenzylisoquinoline alkaloid extracted from Stephania genus of Menispermaceae family. Stephania cerebroside has multiple physiological activities such as anti-inflammatory, analgesic and antiviral, and is widely used to treat various acute and chronic diseases, including radiation-induced leukopenia, idiopathic thrombocytopenic purpura, alopecia areata, pityriasis, snake bites, xerostomia, sarcoidosis, refractory anemia and various cancer-related diseases.
[0003] At present, the clinical application dosage form of celastrol is mainly oral tablets, but celastrol is not easily absorbed orally and has low bioavailability, which affects its efficacy. According to the prior art "Study on the Absorption Mechanism of celastrol" (Xu Weijuan, Master's thesis of Sichuan University, 2007), "the whole animal experiment investigated the in vivo pharmacokinetic process of celastrol after intravenous injection and oral gavage. After intravenous injection of celastrol solution, the blood drug concentration values at each time point were analyzed and fitted by DAS software. The results showed that celastrol is a two-compartment model drug. After gavage of celastrol, the blood drug concentration values at each time point were analyzed and fitted by DAS2.0 software. The results showed that celastrol is a two-compartment model drug. The absolute bioavailability of celastrol in rats is 1.02%. The blood drug concentration is low after oral administration, and the bioavailability is low"; therefore, providing a new dosage form of celastrol with higher bioavailability is a problem that needs to be solved in this field. Summary of the invention
[0004] In view of this, the object of the present invention is to provide a cephalaenopsis preparation and a preparation method thereof. The cephalaenopsis preparation provided by the present invention utilizes cephalaenopsis and β-cyclodextrin to form an inclusion compound, which can improve the utilization of cephalaenopsis. Furthermore, the oral administration of the cephalaenopsis preparation provided by the present invention can also improve the bioavailability of cephalaenopsis.
[0005] The invention provides a cephalaenopsis preparation, comprising the following components in parts by weight: 30-45 parts of cephalaenopsis, 30-45 parts of beta-cyclodextrin, 2-4 parts of aspartame, 10-15 parts of dextrin, 1-6 parts of sodium carboxymethyl starch and 2-10 parts of talc.
[0006] Preferably, the composition comprises the following components in parts by weight: 38-42 parts of cephaladin, 38-42 parts of β-cyclodextrin, 2.5-3.5 parts of aspartame, 12-14 parts of dextrin, 2-3 parts of sodium carboxymethyl starch, and 3-5 parts of talc.
[0007] Preferably, the dosage form of the cephalad preparation is a buccal tablet.
[0008] Preferably, the mass percentage of stephania in the stephania preparation is 38-42%.
[0009] The present invention provides a method for preparing the cephalaenopsis preparation, comprising the following steps:
[0010] The stephaniocelin and β-cyclodextrin are mixed and ground to obtain a stephaniocelin-β-cyclodextrin inclusion complex;
[0011] The cephalaenopsis indole-β-cyclodextrin inclusion compound, aspartame, dextrin and sodium carboxymethyl starch are mixed to obtain a mixed powder;
[0012] The mixed powder and talcum powder are mixed and tableted to obtain a cephalaenopsis preparation.
[0013] Preferably, the grinding time is 25 to 35 minutes.
[0014] Preferably, the cephaladin-β-cyclodextrin inclusion complex, aspartame, dextrin, and sodium carboxymethyl starch are mixed by an equal amount incremental method.
[0015] Compared with the prior art, the present invention has the following beneficial effects: the cephalaenoside preparation provided by the present invention uses cephalaenoside and β-cyclodextrin to form an inclusion compound, which can improve the utilization of cephalaenoside, and at the same time, the cephalaenoside-β-cyclodextrin inclusion compound greatly improves the taste of the buccal tablets, and the mouthfeel is good; further, the buccal administration method of the cephalaenoside preparation provided by the present invention can also improve the bioavailability of cephalaenoside. According to the examples, the absolute bioavailability of the cephalaenoside buccal tablets provided by the present invention is 27.6%, which significantly improves the bioavailability of cephalaenoside.
[0016] Various raw materials in the cephalaenopsis preparation provided by the invention all comply with national or local standards, the preparation process is simple and convenient, there is no side effect, and it is easy to implement and promote. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 The curve diagram of the average blood drug concentration of cephalaenopsis in beagle dogs after intravenous administration of 2 mg / kg and oral administration of 6 mg / kg;
[0018] Figure 2 These are the drug dissolution curves of cephalaenopsis lozenges using pH 6.8 phosphate buffer and pH 6.8 simulated artificial saliva as dissolution media. DETAILED DESCRIPTION
[0019] The invention provides a cephalaenopsis preparation, comprising the following components in parts by weight: 30-45 parts of cephalaenopsis, 30-45 parts of beta-cyclodextrin, 2-4 parts of aspartame, 10-15 parts of dextrin, 1-6 parts of sodium carboxymethyl starch and 2-10 parts of talc.
[0020] In the present invention, the cephalanthrin preparation includes 30 to 45 parts of cephalanthrin, preferably 38 to 42 parts, and more preferably 40 parts; cephalanthrin is isolated from plants of the genus cephalanthus of the Menispermaceae family, and is a dibenzylisoquinoline alkaloid, mainly found in plants such as the genus Stephania and the golden thread hanging turtle. Cephalanthrin is mainly used for anti-inflammatory, immunomodulatory and treatment of acute and chronic diseases such as leukopenia, and this drug from natural plants is well tolerated and can be administered orally or intravenously for a long time in large doses, with almost no adverse reactions.
[0021] In the present invention, the cephalad preparation includes 30 to 45 parts of β-cyclodextrin, preferably 38 to 42 parts, and more preferably 40 parts; β-cyclodextrin as a new pharmaceutical excipient is mainly used to increase the stability of drugs, prevent drug oxidation and decomposition, improve drug solubility and bioavailability, reduce drug toxicity and side effects, and mask the peculiar smell and odor of drugs.
[0022] In the present invention, the cephalanthrin and β-cyclodextrin form a cephalanthrin-β-cyclodextrin inclusion complex, which can improve the bioavailability of cephalanthrin on the one hand, and improve the taste and mouthfeel of the cephalanthrin buccal tablets on the other hand.
[0023] In the present invention, the cephalaenoside preparation includes 2 to 4 parts of aspartame, preferably 2.5 to 3.5 parts, and more preferably 5 parts; aspartame is an artificial sweetener, a natural functional oligosaccharide, 200 times sweeter than ordinary sucrose, not easy to deliquesce, not causing tooth decay, and edible for diabetic patients. In the present invention, aspartame is used as a sweetener to adjust the taste of the cephalaenoside buccal tablet.
[0024] In the present invention, the cephalad preparation includes 10 to 15 parts of dextrin, preferably 12 to 14 parts; dextrin is usually used as a binder for tablets; it is insoluble in alcohol, easily soluble in water, and has strong viscosity when dissolved in water. In the present invention, the dextrin is used as a binder.
[0025] In the present invention, the cephalaenopsis preparation includes 1 to 6 parts of sodium carboxymethyl starch, preferably 2 to 3 parts; sodium carboxymethyl starch is a water-soluble anionic polymer compound, tasteless, non-toxic, and not easy to mold; it has strong water absorption and swelling properties, can swell quickly in cold water, and after absorbing water, the particles swell without dissolving, do not form a colloidal solution, and do not hinder the continued penetration of water to affect the further disintegration of the tablets, so it can be used as an efficient disintegrant and excipient for insoluble drugs and soluble drug tablets. In the present invention, the sodium carboxymethyl starch is used as a disintegrant.
[0026] In the present invention, the cephalaenopsis preparation includes 2 to 10 parts of talc, preferably 3 to 5 parts; talc is non-toxic, tasteless, has good compatibility, strong gloss, soft taste, strong smoothness, and will not degrade the original product. In the present invention, the talc is used as a lubricant.
[0027] In the present invention, the dosage form of the cepharanthin preparation is a buccal tablet; the administration form of the buccal tablet can improve the bioavailability of cepharanthin.
[0028] The present invention provides a method for preparing the cephalaenoside preparation, comprising the following steps: mixing cephalaenoside with β-cyclodextrin, grinding to obtain a cephalaenoside-β-cyclodextrin inclusion compound; mixing the cephalaenoside-β-cyclodextrin inclusion compound, aspartame, dextrin, and sodium carboxymethyl starch to obtain a mixed powder; mixing the mixed powder with talcum powder, and tableting to obtain the cephalaenoside preparation.
[0029] In the present invention, cepharanthin and β-cyclodextrin are mixed and ground to obtain cepharanthin-β-cyclodextrin inclusion complex; the grinding time is preferably 25 to 35 minutes, more preferably 28 to 32 minutes, and more preferably 30 minutes. In the present invention, the grinding is preferably performed using a mortar.
[0030] After obtaining the cephalaenopsis-β-cyclodextrin inclusion compound, the present invention mixes the cephalaenopsis-β-cyclodextrin inclusion compound, aspartame, dextrin and sodium carboxymethyl starch to obtain a mixed powder; the mixing is preferably carried out by an equal amount incremental method.
[0031] After obtaining the mixed powder, the mixed powder and talcum powder are mixed and tableted to obtain the cepharanthin preparation. In the present invention, the tableting is preferably performed using a rotary tablet press. The present invention has no special limitation on the tableting operation, and conventional tableting operations in the art can be used.
[0032] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.
[0033] Example 1
[0034] Formula composition: Each 150mg lozenge contains 60mg of cephalaenopsis, 60mg of β-cyclodextrin, 5mg of aspartame, 20mg of dextrin, 2mg of sodium carboxymethyl starch, and 3mg of talc.
[0035] The preparation method of the cephalaenopsis buccal tablets provided in this embodiment is as follows:
[0036] Weigh 60 mg of cephalaenopsis indole and 60 mg of β-cyclodextrin, grind them together for 30 min to form a cephalaenopsis indole-β-cyclodextrin inclusion complex;
[0037] The cephalaenopsis acetosine-β-cyclodextrin inclusion compound powder was mixed with 5 mg of aspartame, 20 mg of dextrin, and 2 mg of sodium carboxymethyl starch in an equal amount stepwise addition method to obtain a mixed powder;
[0038] The mixed powder was mixed with 3 mg of talc powder, and tableted to obtain the cephaladin buccal tablet.
[0039] Example 2
[0040] Formula composition: Each 200 mg lozenge contains 70 mg of cephalaenopsis, 70 mg of β-cyclodextrin, 10 mg of aspartame, 35 mg of dextrin, 5 mg of sodium carboxymethyl starch, and 10 mg of talc.
[0041] The preparation method of the cephalaenopsis buccal tablets provided in this embodiment is as follows:
[0042] Weigh 70 mg of cephalaenopsis indole and 70 mg of β-cyclodextrin, grind them together for 30 min to form a cephalaenopsis indole-β-cyclodextrin inclusion complex;
[0043] The cephalaenopsis cephalaenopsis-β-cyclodextrin inclusion compound powder was mixed with 10 mg of aspartame, 35 mg of dextrin, and 5 mg of sodium carboxymethyl starch in an equal amount stepwise addition method to obtain a mixed powder;
[0044] The mixed powder was mixed with 10 mg of talcum powder, and tableted to obtain the cephalad lozenges.
[0045] Example 3
[0046] Formula composition: Each 250mg lozenge contains 75mg of cephalaenopsis, 75mg of β-cyclodextrin, 20mg of aspartame, 40mg of dextrin, 15mg of sodium carboxymethyl starch, and 25mg of talc.
[0047] The preparation method of the cephalaenopsis buccal tablets provided in this embodiment is as follows:
[0048] Weigh 75 mg of cephalaenopsis indole and 75 mg of β-cyclodextrin, grind them together for 30 min to form a cephalaenopsis indole-β-cyclodextrin inclusion complex;
[0049] The cephalaenopsis cephalaenopsis-β-cyclodextrin inclusion compound powder was mixed with 20 mg of aspartame, 40 mg of dextrin, and 15 mg of sodium carboxymethyl starch in an equal amount stepwise addition method to obtain a mixed powder;
[0050] The mixed powder was mixed with 25 mg of talc powder, and tableted to obtain the cephaladin buccal tablet.
[0051] Comparative Example 1
[0052] Formula composition: Each 150mg lozenge contains 60mg of cephalaenopsis, 20mg of lactose, 40mg of mannitol, 5mg of aspartame, 20mg of dextrin, 2mg of sodium carboxymethyl starch, and 3mg of talc.
[0053] The preparation method of the cephalaenopsis buccal tablets provided in this comparative example is as follows:
[0054] Weigh 60 mg of cephalaenopsis indica, 20 mg of lactose, 40 mg of mannitol, 5 mg of aspartame, 20 mg of dextrin, and 2 mg of sodium carboxymethyl starch, mix them in equal amounts, add appropriate amount of water, grind in a mortar for 30 minutes, and prepare a soft material;
[0055] The soft material obtained above was granulated through a 20-mesh sieve, and then dried in an oven at 50°C for 4 hours;
[0056] The dried powder was evenly mixed with 3 mg of talcum powder, and tableted to obtain the cephaladin buccal tablet.
[0057] Comparative Example 2
[0058] Formula composition: Each 200 mg lozenge contains 70 mg of cephalaenopsis, 23 mg of lactose, 47 mg of mannitol, 10 mg of aspartame, 35 mg of dextrin, 5 mg of sodium carboxymethyl starch, and 10 mg of talc.
[0059] The preparation method of the cephalaenopsis buccal tablets provided in this comparative example is as follows:
[0060] Weigh 70 mg of cephalaenopsis indica, 23 mg of lactose, 47 mg of mannitol, 10 mg of aspartame, 35 mg of dextrin, and 5 mg of sodium carboxymethyl starch, mix them in equal amounts, add appropriate amount of water, grind in a mortar for 30 minutes, and prepare a soft material;
[0061] The soft material obtained above was granulated through a 20-mesh sieve, and then dried in an oven at 50°C for 4 hours;
[0062] The dried powder was evenly mixed with 10 mg of talcum powder, and tableted to obtain the cephaladin buccal tablet.
[0063] Comparative Example 3
[0064] Formula composition: Each 250mg lozenge contains 75mg of cephalaenopsis, 25mg of lactose, 50mg of mannitol, 20mg of aspartame, 40mg of dextrin, 15mg of sodium carboxymethyl starch, and 25mg of talc.
[0065] The preparation method of the cephalaenopsis buccal tablets provided in this comparative example is as follows:
[0066] Weigh 75 mg of cephalaenopsis indica, 25 mg of lactose, 50 mg of mannitol, 20 mg of aspartame, 40 mg of dextrin, and 15 mg of sodium carboxymethyl starch, mix them in equal amounts, add appropriate amount of water, grind in a mortar for 30 minutes, and prepare a soft material;
[0067] The soft material obtained above was granulated through a 20-mesh sieve, and then dried in an oven at 50°C for 4 hours;
[0068] The dried powder was evenly mixed with 25 mg of talcum powder, and tableted to obtain the cephaladin buccal tablet.
[0069] The appearance and taste of the cephalaenoside buccal tablets of Examples 1-3 and Comparative Examples 1-3 were evaluated. The evaluation results are shown in Table 1.
[0070] Table 1 Evaluation results of the cephalaenoside buccal tablets prepared in Example
[0071]
[0072]
[0073] The weight of the buccal tablets prepared in Example 1 was appropriate, and the appearance and taste scores were high; the weight of the tablets in Examples 2 and 3 was relatively large, not suitable for tableting, and prone to tablet cracking, so the scores were relatively low. Comparative Examples 1 to 3 replaced β-cyclodextrin, could not form inclusion complexes, had poor taste, and had low scores.
[0074] The physical and chemical evaluation standards were implemented in accordance with the Pharmacopoeia of the People’s Republic of China (2020 edition), and the test results are shown in Table 2.
[0075] Table 2 Physical and chemical evaluation results of the cephalaenoside buccal tablets prepared in Example
[0076]
[0077] Experimental Example 1
[0078] Bioavailability of cephalaenopsis buccal tablets in beagle dogs
[0079] 1. Preparation of test drugs
[0080] (1) Cephalaenopsis buccal tablets: prepared according to Example 1
[0081] (2) Cephalaenopsis solution: Weigh cephalaenopsis and prepare a 10 mg / mL cephalaenopsis solution with physiological saline (pH adjusted to 3.5 with acetic acid).
[0082] 2. Experimental Design
[0083] Four beagle dogs were randomly divided into two groups, group A and group B, with 2 dogs in each group. The experiment adopted a double-dose, double-cycle, double-sequence crossover design. In the first cycle, dogs in group A were given 1 tablet of cephalaenoside buccal tablet, and dogs in group B were intravenously injected with 2 mL of cephalaenoside solution. In the second cycle, dogs in group A were intravenously injected with 2 mL of cephalaenoside solution, and dogs in group B were given 1 tablet of cephalaenoside buccal tablet. The interval between the two phases of administration was 10 days.
[0084] The subjects were fasted for 12 hours before administration and were allowed to eat and drink water freely 4 hours after administration.
[0085] Time points for oral blood collection: 15min, 0.5h, 1h, 1.5h, 2h, 4h, 6h, 8h, 12h, 24h, 32h, and 48h after administration.
[0086] Time points for venous blood collection: 1min, 5min, 15min, 0.5h, 1h, 2h, 4h, 6h, 8h, 12h, 24h, 32h, and 48h after administration.
[0087] 1 mL of blood was collected from the cephalic vein of the forelimb and placed in a 1.5 mL anticoagulant tube, and mixed by inversion 2-3 times. Centrifuge at 4°C, 8000 r / min for 10 min, take the supernatant, store at -20°C, and use it for testing blood drug concentration.
[0088] Blood drug concentration detection method:
[0089] Detection was performed as described in the following chromatographic conditions and mass spectrometric conditions.
[0090] Instrument: SCIEX Triple Quad 6500+LC-MS / MS;
[0091] 1) Chromatographic conditions:
[0092] Chromatographic column: ACQUITY UPLC BEH C18 (2.1 mm × 50 mm, 1.7 μm);
[0093] Column temperature: 45°C;
[0094] Flow rate: 200 μL / min;
[0095] Injection volume: 5 μL;
[0096] Sample chamber temperature: 8°C;
[0097] Analysis time: 4 min;
[0098] Mobile phase: Phase A: water (containing 0.1% (v / v) formic acid), Phase B: methanol (containing 0.1% (v / v) formic acid);
[0099] Gradient elution conditions: see Table 3;
[0100] Table 3 Gradient elution conditions
[0101] Time (min) A(%) B(%) Time (min) A(%) B(%) 0.0 90 10 2.1 10 90 0.5 90 10 2.3 90 10 1.0 10 90 2.5 10 90 1.5 10 90 2.7 10 90 1.7 90 10 2.71 90 10 1.9 10 90 4.0 90 10
[0102] 2) Mass spectrometry conditions:
[0103] Detailed mass spectrometry conditions are shown in Table 4.
[0104] Table 4 Mass spectrometry conditions of cephalaenopsis and internal standard (CS55)
[0105]
[0106] 3. Experimental results
[0107] The curve of the average blood drug concentration of cephalaenopsis in beagle dogs after intravenous administration of 2 mg / kg and oral administration of 6 mg / kg is shown in Figure 1 The calculated bioavailability of the buccal tablet is 27.6%, which is significantly higher than conventional oral administration.
[0108] The pharmacokinetic parameters of cephalaenopsis in beagle dogs after intravenous and oral administration are shown in Table 5.
[0109] Table 5 Pharmacokinetic parameters of cephalaenopsis in beagle dogs after intravenous and oral administration (n=4, mean±SD)
[0110]
[0111]
[0112] Experimental Example 2
[0113] Evaluation of the dissolution rate of cephalaenopsis buccal tablets
[0114] 1. Experimental Methods
[0115] According to the NMPA technical guidelines for dissolution testing of common oral solid preparations, the slurry method was selected to evaluate the dissolution of cephalaenopsis buccal tablets.
[0116] 2. Experimental conditions
[0117] Temperature: 37±0.5℃; rotation speed: 75r / min; sampling time: 5, 10, 15, 20, 30, 45, 60, 90min.
[0118] 3. Dissolution medium
[0119] pH 6.8 phosphate buffer: Mix 250 mL of 0.2 mol / L potassium dihydrogen phosphate solution with 118 mL of 0.2 mol / L sodium hydroxide solution, then add water to dilute to 1000 mL and shake well.
[0120] pH 6.8 simulated artificial saliva: weigh 8g sodium chloride, 0.19g potassium dihydrogen phosphate, and 2.38g sodium dihydrogen phosphate, dissolve them in 1L water, and then adjust the solution pH to 6.8 with phosphoric acid.
[0121] 4. Experimental Results
[0122] The dissolution curves of cepharanthine buccal tablets using pH 6.8 phosphate buffer and pH 6.8 simulated artificial saliva as dissolution media are shown in Figure 2. Figure 2 More than 80% of the cephalaenopsis lozenges were dissolved within 30 min and showed a stable release curve.
[0123] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. A cephalaenopsis preparation, characterized in that The invention is composed of the following components in parts by weight: 30-45 parts of cephalaenopsis, 30-45 parts of β-cyclodextrin, 2-4 parts of aspartame, 10-15 parts of dextrin, 1-6 parts of sodium carboxymethyl starch, and 2-10 parts of talc; The preparation method of the cephalaenopsis preparation comprises the following steps: The stephaniocelin and β-cyclodextrin are mixed and ground to obtain a stephaniocelin-β-cyclodextrin inclusion compound; the stephaniocelin-β-cyclodextrin inclusion compound, aspartame, dextrin, and sodium carboxymethyl starch are mixed to obtain a mixed powder; the grinding time is 25 to 35 minutes; The mixed powder and talcum powder are mixed and tableted to obtain a cephalaenopsis preparation; The dosage form of the cephalaenopsis preparation is a buccal tablet; The mass percentage of stephania in the stephania preparation is 38-42%.
2. The cepharanthin preparation according to claim 1, characterized in that The invention is composed of the following components in parts by weight: 38-42 parts of cephalaenopsis, 38-42 parts of beta-cyclodextrin, 2.5-3.5 parts of aspartame, 12-14 parts of dextrin, 2-3 parts of sodium carboxymethyl starch and 3-5 parts of talc.
3. The method for preparing the cepharanthin preparation according to claim 1 or 2, characterized in that: The following steps are involved: The stephaniocelin and β-cyclodextrin are mixed and ground to obtain a stephaniocelin-β-cyclodextrin inclusion compound; the stephaniocelin-β-cyclodextrin inclusion compound, aspartame, dextrin, and sodium carboxymethyl starch are mixed to obtain a mixed powder; The mixed powder and talcum powder are mixed and tableted to obtain a cephalaenopsis preparation.
4. The preparation method according to claim 3, characterized in that: The grinding time is 25 to 35 minutes.
5. The preparation method according to claim 3, characterized in that: The cephalaenopsis acetosine-β-cyclodextrin inclusion compound, aspartame, dextrin and sodium carboxymethyl starch are mixed by an equal amount incremental method.
